Patents by Inventor John Devane

John Devane has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12011502
    Abstract: Injectable baclofen formulations and methods that are bioequivalent in terms of plasma baclofen exposure to oral dosage forms but with reduced exposure ratios of baclofen to the M1 metabolite.
    Type: Grant
    Filed: November 9, 2022
    Date of Patent: June 18, 2024
    Assignee: AMNEAL PHARMACEUTICALS LLC
    Inventors: Leonard O'Mahony, John Devane, Sharon Hamm, David Penake
  • Patent number: 11931328
    Abstract: Pharmaceutical compositions including an active ingredient and a stabilizer, as well as methods of manufacture of the compositions, and methods of their use. The composition may include the active ingredient dispersed throughout a matrix of the stabilizer. In some embodiments, the active ingredient and the stabilizer are intimately mixed in a matrix formulation. In some embodiments, the active ingredient is selected from 4 amino-3-(4-chlorophenyl)butanoic acid) (“baclofen”) and its pharmaceutically acceptable salts.
    Type: Grant
    Filed: March 16, 2023
    Date of Patent: March 19, 2024
    Assignee: AMNEAL PHARMACEUTICALS LLC
    Inventors: David Penake, Sharon Hamm, Leonard O'Mahony, John Devane, Wolfgang Mohr, Manuel Weinheimer
  • Patent number: 11850225
    Abstract: Baclofen formulations, including formulations that minimize variability between doses, that minimize variation in patient exposure baclofen metabolites, and are bioequivalent in regards to baclofen versus M1 metabolite ratios of baclofen tablets.
    Type: Grant
    Filed: July 11, 2022
    Date of Patent: December 26, 2023
    Assignee: AMNEAL PHARMACEUTICALS LLC
    Inventors: Leonard O'Mahony, Sharon Hamm, John Devane, David Penake, Wolfgang Mohr, Manuel Weinheimer
  • Patent number: 11654124
    Abstract: Pharmaceutical compositions including an active ingredient and a stabilizer, as well as methods of manufacture of the compositions, and methods of their use. The composition may include the active ingredient dispersed throughout a matrix of the stabilizer. In some embodiments, the active ingredient and the stabilizer are intimately mixed in a matrix formulation. In some embodiments, the active ingredient is selected from 4 amino-3-(4-chlorophenyl)butanoic acid) (“baclofen”) and its pharmaceutically acceptable salts.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: May 23, 2023
    Assignee: AMNEAL PHARMACEUTICALS LLC
    Inventors: David Penake, Sharon Hamm, Leonard O'Mahony, John Devane, Wolfgang Mohr, Manuel Weinheimer
  • Patent number: 11523984
    Abstract: Injectable baclofen formulations and methods that are bioequivalent in terms of plasma baclofen exposure to oral dosage forms but with reduced exposure ratios of baclofen to the M1 metabolite.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: December 13, 2022
    Assignee: AMNEAL PHARMACEUTICALS LLC
    Inventors: Leonard O'Mahony, John Devane, Sharon Hamm, David Penake
  • Patent number: 11491125
    Abstract: Baclofen formulations, including formulations that minimize variability between doses, that minimize variation in patient exposure to baclofen metabolites, and are bioequivalent in regards to baclofen versus M1 metabolite ratios of baclofen tablets.
    Type: Grant
    Filed: September 29, 2021
    Date of Patent: November 8, 2022
    Assignee: AMNEAL PHARMACEUTICALS LLC
    Inventors: Leonard O'Mahony, Sharon Hamm, John Devane, David Penake
  • Patent number: 11083694
    Abstract: Phenol formulations including phenol and an encapsulation agent, such as a cyclodextrin or derivatives thereof, and uses of such formulations.
    Type: Grant
    Filed: January 28, 2021
    Date of Patent: August 10, 2021
    Assignee: SAOL INTERNATIONAL DEVELOPMENT LTD.
    Inventors: Leonard O'Mahony, Sharon Hamm, John Devane, Imran Ahmed, David Penake
  • Patent number: 11083695
    Abstract: Phenol formulations including phenol and an encapsulation agent, such as a cyclodextrin or derivatives thereof, and uses of such formulations.
    Type: Grant
    Filed: January 28, 2021
    Date of Patent: August 10, 2021
    Assignee: SAOL INTERNATIONAL DEVELOPMENT LTD.
    Inventors: Leonard O'Mahony, Sharon Hamm, John Devane, Imran Ahmed, David Penake
  • Patent number: 10959962
    Abstract: Phenol formulations including phenol and an encapsulation agent, such as a cyclodextrin or derivatives thereof, and uses of such formulations.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: March 30, 2021
    Assignee: SAOL INTERNATIONAL DEVELOPMENT LTD.
    Inventors: Leonard O'Mahony, Sharon Hamm, John Devane, Imran Ahmed, David Penake
  • Patent number: 10792262
    Abstract: Pharmaceutical compositions including an active ingredient and a stabilizer, as well as methods of manufacture of the compositions, and methods of their use.
    Type: Grant
    Filed: July 29, 2019
    Date of Patent: October 6, 2020
    Assignee: SAOL INTERNATIONAL LIMITED
    Inventors: David Penake, Sharon Hamm, Leonard O'Mahony, John Devane, Wolfgang Mohr, Manuel Weinheimer
  • Patent number: 10751312
    Abstract: Pharmaceutical compositions including an active ingredient and a stabilizer, as well as methods of manufacture of the compositions, and methods of their use.
    Type: Grant
    Filed: July 29, 2019
    Date of Patent: August 25, 2020
    Assignee: SAOL INTERNATIONAL LIMITED
    Inventors: David Penake, Sharon Hamm, Leonard O'Mahony, John Devane, Wolfgang Mohr, Manuel Weinheimer
  • Publication number: 20150164893
    Abstract: The present invention relates to formulations comprising therapeutically effective amounts of at least one acid-stable, carrier-mediated transport statin, at least one poorly water-soluble, carrier-mediated transport statin, or at least one large molecular weight, carrier-mediated transport statin, such as atorvastatin and rosuvastatin, or a pharmaceutically acceptable salt thereof, and methods of their use. The present formulations and methods are designed to exhibit a controlled-release of a therapeutic amount of the statin in the small intestine, thereby limiting systemic exposure of the statin and maximizing liver-specific absorption of the drug. The formulations and methods of the present invention are particularly useful for treating and/or preventing conditions that are benefited by decreasing levels of lipids and/or cholesterol in the body.
    Type: Application
    Filed: February 23, 2015
    Publication date: June 18, 2015
    Inventors: Jackie Butler, John Devane, Paul Stark
  • Patent number: 9040591
    Abstract: The present invention is directed to methods and formulations for treating, modifying, and/or managing gastrointestinal secretion, and intestinal conditions that cause the same. Methods of using at least one ?3 ?4 nAChR antagonist and formulations comprising at least one ?3 ?4 nAChR antagonist, or pharmaceutically acceptable salt thereof, are included.
    Type: Grant
    Filed: July 19, 2012
    Date of Patent: May 26, 2015
    Assignee: AGI Therapeutics Public Limited Company
    Inventor: John Devane
  • Patent number: 8987322
    Abstract: The present invention relates to formulations comprising therapeutically effective amounts of at least one acid-stable, carrier-mediated transport statin, at least one poorly water-soluble, carrier-mediated transport statin, or at least one large molecular weight, carrier-mediated transport statin, such as atorvastatin and rosuvastatin, or a pharmaceutically acceptable salt thereof, and methods of their use. The present formulations and methods are designed to exhibit a controlled-release of a therapeutic amount of the statin in the small intestine, thereby limiting systemic exposure of the statin and maximizing liver-specific absorption of the drug. The formulations and methods of the present invention are particularly useful for treating and/or preventing conditions that are benefited by decreasing levels of lipids and/or cholesterol in the body.
    Type: Grant
    Filed: October 19, 2004
    Date of Patent: March 24, 2015
    Assignee: Circ Pharma Research and Development Limited
    Inventors: Jackie Butler, John Devane, Paul Stark
  • Publication number: 20130030057
    Abstract: The present invention is directed to methods and formulations for treating, modifying, and/or managing gastrointestinal secretion, and intestinal conditions that cause the same. Methods of using at least one ?3 ?4 nAChR antagonist and formulations comprising at least one ?3 ?4 nAChR antagonist, or pharmaceutically acceptable salt thereof, are included.
    Type: Application
    Filed: July 19, 2012
    Publication date: January 31, 2013
    Inventor: John Devane
  • Publication number: 20120070472
    Abstract: Chronotherapeutic formulations of cardiovascular drugs are disclosed. The formulations comprise at least one cardiovascular drug that exhibits an in vivo elimination half-life of less than about 8 hours; wherein the formulation exhibits the following in vivo profile following administration to a subject: a) a delay in release of therapeutic levels of the at least one drug for about 2 to about 8 hours; b) a Tmax at about 8 to about 12 hours; c) a drug plasma level within 50% of the peak for greater than or equal to 12 hours; and d) a peak-to-trough ratio of drug plasma levels greater than or equal to about 4.
    Type: Application
    Filed: October 11, 2011
    Publication date: March 22, 2012
    Applicant: Circ Pharma Research & Development Limited
    Inventors: John Devane, Jackie Butler
  • Patent number: 7928092
    Abstract: Methods and formulations for treating inflammatory bowel disease are disclosed. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of 4-aminosalicylic acid and/or 5-aminosalicylic acid to affected areas of the intestine. The methods and formulations comprise modified-release elements, providing for drug delivery to the affected or desired area. Diseases and conditions treatable with the present invention include Crohn's disease and ulcerative colitis.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: April 19, 2011
    Assignee: AGI Therapeutics Ltd.
    Inventors: John Devane, Jackie Butler
  • Publication number: 20100278917
    Abstract: Methods and formulations for treating inflammatory bowel disease are disclosed. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of 4-aminosalicylic acid and/or 5-aminosalicylic acid to affected areas of the intestine. The methods and formulations comprise modified-release elements, providing for drug delivery to the affected or desired area. Diseases and conditions treatable with the present invention include Crohn's disease and ulcerative colitis.
    Type: Application
    Filed: June 10, 2010
    Publication date: November 4, 2010
    Inventors: John Devane, Jackie Butler
  • Patent number: 7825106
    Abstract: Methods and formulations for treating inflammatory bowel disease are disclosed. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of 4-aminosalicylic acid and/or 5-aminosalicylic acid, and pharmaceutically acceptable salts and pro-drugs thereof, to affected areas of the intestine, i.e., distal gut. The methods and formulations comprise modified-release elements, providing for drug delivery to the affected or desired area. Diseases and conditions treatable with the present invention include Crohn's disease and ulcerative colitis.
    Type: Grant
    Filed: March 10, 2006
    Date of Patent: November 2, 2010
    Assignee: AGI Therapeutics Ltd.
    Inventors: John Devane, Jackie Butler
  • Publication number: 20100196479
    Abstract: The present invention is directed to methods and formulations for treating, modifying, and/or managing gastrointestinal secretion, and intestinal conditions that cause the same. Methods of using at least one ?3 ?4 nAChR antagonist and formulations comprising at least one ?3 ?4 nAChR antagonist, or pharmaceutically acceptable salt thereof, are included.
    Type: Application
    Filed: March 16, 2010
    Publication date: August 5, 2010
    Inventor: John Devane